Latest Breaking News On - Social performance - Page 60 : comparemela.com

Minerva Neurosciences, Inc: Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension (DB+OLE) (N=59) (N=63) NSFS About the trial In the double-blind, placebo-controlled portion of the Phase 3 trial, a total of 515 patients were randomized in a 1:1:1 ratio to 32 mg/day roluperidone, 64 mg/day roluperidone, or placebo for 12 weeks, and 513 patients received study drugs. Of these, 333 patients (65%) entered the 40-week OLE, where patients receiving roluperidone continued to receive the same dose of roluperidone, while patients who received placebo during the double-blind phase were randomized at the beginning of the study to receive either 32 mg or 64 mg during the OLE. A total of 166 patients were treated with the 32 mg dose, and 167 patients with the 64 mg dose. A total of 202 of the 333 patients entering the OLE (61%) completed the 40-wee

Minerva neurosciencesWilliamb boniNational institute of mental healthMinerva neurosciences incCompany typeNegative syndrome scaleMarder negative symptom factor scoreSocial performanceOpen label extensionBrief assessmentBrief negative symptom scaleNational instituteMental healthமினெர்வா நரம்பியல்தேசிய நிறுவனம் ஆஃப் மன ஆரோக்கியம்மினெர்வா நரம்பியல் இன்க்